Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

pembrolizumab 4Nivolumab 3toripalimab 2sintilimab 2Neoadjuvant Therapy 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1durvalumab 1denileukin diftitox 1danvatirsen 1camrelizumab 1avelumab 1atezolizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Turcot syndrome × tislelizumab × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡